All In Biotech

Drug Trial Radar · NCT01678872

A Follow-up Study to Evaluate the Safety of RetinoStat® in Patients With Age-Related Macular Degeneration

A Long Term Follow-up Study to Evaluate the Safety of RetinoStat® in Patients With Age-Related Macular Degeneration

Last checked: Nov 20, 2026Latest source record: Jan 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

18

Planned (sponsor's estimate)

Start

Aug 2012

Primary completion

Mar 2029

Study completion Mar 2029

Sponsor

Lead sponsor
Oxford BioMedicaIndustry
Sponsor type
Industry
First posted
Sep 5, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Other
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to examine the long term safety of an experimental gene transfer agent, RetinoStat®, designed to treat neovascular age-related macular degeneration.

Conditions

  • Age-Related Macular Degeneration

Interventions

  • RetinoStatDrug

    Long Term Follow up of patients who received RetinoStat in a previous study

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The incidence of adverse eventsTime frame: 14 years

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • University of Iowa Hospitals & Clinics

    Iowa City, Iowa

  • John Hopkins University Hospital

    Baltimore, Maryland

  • Oregon Health & Science University

    Portland, Oregon

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.